Oncology

forest

Biotech

Treeline sees path to public markets via reverse merger

The deal is expected to close in the second half of this year and should leave Treeline with $900 million in cash, enough to last into 2029.

Darren Incorvaia Jun 8, 2026 10:37am

more expensive

Regeneron pays $37M, adds $2B in biobucks to expand CytomX pact

Jun 3, 2026 9:48am

Step closer race run

ASCO: Cardiff posts updated colorectal data before pivotal push

Jun 2, 2026 9:06am

Takeda

ASCO: Takeda touts ‘tremendous potential’ of Innovent bispecific

Jun 2, 2026 4:30am

Novartis booth at AACR 2026

Has Novartis’ T-Charge push been overtaken by in vivo CAR-Ts?

May 22, 2026 8:28am

IPO initial public offering

Parabilis, fresh from inking Regeneron pact, plans IPO

May 20, 2026 5:25am

More News

Clinical trial flaws ‘being scaled, not solved’ by AI: report

May 19, 2026 10:48am

Model Meds aims to ‘discover new colors’ in drug discovery quest

May 15, 2026 9:45am

BMS inks $15B deal to bag Hengrui assets, tap China’s R&D speed

May 12, 2026 1:56am

BeOne shelves 5 cancer programs, halts ph. 2 arthritis trial

May 7, 2026 11:15am

See more stories